导读

一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。医脉通精选了泌尿肿瘤领域Oral Abstract Session部分的13项重磅研究及Poster Session部分入选的8项中国研究，小编带您先睹为快。

口头报告专场（Oral Abstract Session）

前列腺/睾丸/阴茎肿瘤

摘要号：LBA5000

标题：Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.

报告人：Alberto Bossi

摘要号：5004

标题：TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.

报告人：Karim Fizazi

摘要号：5005

标题：LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).

报告人：Shahneen Sandhu

口头报告专场（Oral Abstract Session）

LBA4619的演示及讨论

摘要号：LBA4619

标题：Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).

报告人：Yohann Loriot

口头报告专场（Oral Abstract Session）

肾脏/膀胱肿瘤

摘要号：LBA4500

标题：Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.

报告人：Toni K. Choueiri

摘要号：LBA4501

标题：Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

报告人：Brian I. Rini

摘要号：4502

标题：Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

报告人：Thomas E. Hutson

摘要号：4503

标题：Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.

报告人：Enrique Grande

摘要号：4504

标题：Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.

报告人：Arlene O. Siefker-Radtke

摘要号：4505

标题：Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

报告人：Shilpa Gupta

摘要号：4506

标题：Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.

报告人：Robert J. Motzer

摘要号：LBA4507

标题：Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.

报告人：Christian Pfister

摘要号：LBA4508

标题：SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.

报告人：Seth P. Lerner

壁报专场（Poster Session）

前列腺/睾丸/阴茎肿瘤

摘要号：5057

海报号：151

标题：Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with metastatic castration resistant prostate cancer receiving abiraterone (ANGELA): A single-center prospective observational trial.

报告人：朱耀，复旦大学附属肿瘤医院

摘要号：5065

海报号：159

标题：Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.

报告人：叶定伟，复旦大学附属肿瘤医院

壁报专场（Poster Session）

肾脏/膀胱肿瘤

摘要号：4521

海报号：13

标题：Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.

报告人：戴洪海，山东省立医院

摘要号：4533

海报号：25

标题：Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligometastatic renal cell carcinoma.

报告人：刘洋，中山大学肿瘤防治中心

摘要号：4543

海报号：35

标题：Immunoglobulin as a predictive biomarker for the efficacy of immune checkpoint inhibitor combined with VEGF-TKI in metastatic renal cell carcinoma.

报告人：Honglei Cui，中国医学科学院肿瘤医院

摘要号：4566

海报号：58

标题：Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study.

报告人：盛锡楠，北京大学肿瘤医院

摘要号：4585

海报号：77

标题：Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.

报告人：林天歆，中山大学孙逸仙纪念医院

摘要号：TPS4612

海报号：98b

标题：ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC).

报告人：张海梁，复旦大学附属肿瘤医院

备注：排名不分先后，如有遗漏或任何问题，请给我们留言~